Dr. Lal Path Labs vs Peers
- Market cap
- ₹32,569 crore
- P/E
- 60.1
- P/B
- 12.99
- ROE
- 21.6%
- Dividend yield
- 0.46%
Dr. Lal Path Labs ranks 1st by market capitalisation among 8 Healthcare Service Provider companies tracked by ATS. Its largest peers are Vijaya Diagnostic Centre, Metropolis Healthcare and Thyrocare Technologies. Its P/E of 60.1 compares with a peer median of 46.6.
Dr. Lal Path Labs vs Healthcare Service Provider peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Dr. Lal Path Labs | 1,950.50 | -0.70% | 32,569 | 60.1 | 12.99 | 21.6% | +22.0% |
| Vijaya Diagnostic Centre | 1,475.00 | +0.57% | 15,177 | 81.0 | 15.86 | 19.7% | +12.5% |
| Metropolis Healthcare | 545.00 | -1.38% | 11,299 | 56.0 | 7.47 | 13.4% | +12.5% |
| Thyrocare Technologies | 516.55 | -2.50% | 8,222 | 46.6 | 14.04 | 28.8% | +12.5% |
| Nephrocare Health Services | 643.15 | +1.36% | 6,453 | 75.8 | 5.78 | 9.0% | +12.5% |
| 3B Blackbio Dx | 1,640.70 | +4.16% | 1,408 | 25.4 | 4.34 | 20.2% | +12.5% |
| Health X Platform | 284.15 | -0.28% | 904 | 22.5 | 1.41 | 0.2% | +12.5% |
| Gaudium IVF and Women Health | 107.50 | -1.63% | 782 | 33.7 | 3.20 | 16.4% | +12.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 7 October 2026. How this data is compiled.
Dr. Lal Path Labs peer comparison — frequently asked questions
Who are Dr. Lal Path Labs' competitors?
Dr. Lal Path Labs' listed peers in Healthcare Service Provider include Vijaya Diagnostic Centre, Metropolis Healthcare, Thyrocare Technologies, Nephrocare Health Services, 3B Blackbio Dx and Health X Platform, ranked here by market capitalisation.
How does Dr. Lal Path Labs' P/E compare with its peers?
Dr. Lal Path Labs trades at a P/E of 60.1, against a median of 46.6 across the 7 Healthcare Service Provider peers shown.
Which is the largest company among Dr. Lal Path Labs' peers?
By market capitalisation, the largest company in the group is Vijaya Diagnostic Centre at ₹15,177 crore, against ₹32,569 crore for Dr. Lal Path Labs.
Same Data For Peers
Trade Dr. Lal Path Labs With ATS
Track LALPATHLAB live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.